Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
Treatments studied
Part of Cancer clinical trials.
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a well-differentiated grade 3 neuroendocrine tumor confirmed by biopsy or cell test (mostly pancreas, or certain other sites).
- Your tumor must have at least one measurable target spot on CT/MRI that can be measured again later.
- You are age 18 or older and able to sign informed consent.
- Your scans show the cancer has progressed within the last 6 months (or you have a medically significant high-risk situation).
- Your general health is good enough (ECOG 0–1) and major blood/organ tests are within required ranges.
- You can safely get a tumor biopsy at the start (unless an exception applies, like hard-to-reach or very small-only lesions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and a targeted drug (apatinib) for people with advanced lung neuroendocrine tumors that have not been treated before. The goal is to see if this combination can shrink or slow the growth of the tumor.
This Phase 2 trial studies whether combining pembrolizumab with lenvatinib can shrink or control brain metastases in people with triple-negative breast cancer, lung cancer, or other solid tumors. It focuses on patients who have measurable brain lesions that can be followed on MRI.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial is testing a combination of an immunotherapy drug (QL1706), a targeted therapy (lenvatinib), and chemotherapy for people with advanced neuroendocrine carcinoma that started outside the lungs. The goal is to see if this combination can help shrink or slow the cancer.
This trial studies whether cabozantinib plus lanreotide can slow or shrink gastroenteropancreatic neuroendocrine tumors that have gotten worse despite previous treatments. If you qualify, you’ll be closely monitored for tumor response and side effects.
This trial tests a combination of two drugs, lenvatinib and pembrolizumab, for people with anal or rectal cancer that has spread or cannot be removed and has worsened after initial treatment. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.